Efficacy and Safety of Dulaglutide in Older Patients: A Post-hoc Analysis of the REWIND trial

Glycemic Control

Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg in patients age < 65 and ≥ 65 years: post hoc analysis of the AWARD-11 trial

Diabetes Obes Metab

Frias JP, Bonora E, Nevárez Ruiz L, Hsia SH, Jung H, Raha S, Cox DA, Bethel MA, Konig M

doi: 10.1111/dom.14469

Type 2 Diabetes

Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials

J Clin Endocrinol Metab.

DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V

doi: 10.1210/clinem/dgz072.

COMMENTED

Lipids

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Lancet.

Cholesterol Treatment Trialists' Collaboration

doi: org/10.1016/S0140-

Type 2 Diabetes

Effect of Once Weekly Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Different Baseline Glycaemic Patterns: A Post-Hoc Analysis of the AWARD-2 Clinical Trial

Diabetes Obes Metab.

Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE

doi: 10.1111/dom.13844.

Diabetes - General

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Lancet Diabetes Endocrinol.

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR

doi: 10.1016/

Diabetes - GeneralType 2 Diabetes

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Diabetes Care

Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, Malik R, Bethel MA, Cox DA

doi: 10.2337/dc20-1473

Type 2 Diabetes

Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups

Diabetes Obes Metab.

Fuechtenbusch M, Aberle J, Heitmann E, Nicolay C, Jung H

doi: 10.1111/dom.

Diabetes - GeneralGlycemic Control

Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults (LADA): A Post-Hoc Analysis of the AWARD-2, -4, and -5 Trials

Diabetes Obes Metab.

Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC

doi: 10.1111/dom.13237.

Type 2 Diabetes

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Lancet Diabetes Endocrinol.

Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N, PIONEER 10 Investigators.

doi: 10.1016/S2213-8587(20)30074-7.

Related content

Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg in patients age < 65 and ≥ 65 years: post hoc analysis of the AWARD-11 trial

Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Effect of Once Weekly Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Different Baseline Glycaemic Patterns: A Post-Hoc Analysis of the AWARD-2 Clinical Trial

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups

Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults (LADA): A Post-Hoc Analysis of the AWARD-2, -4, and -5 Trials

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial